Bone Biologics extended validated shelf life for rhNELL-1 to 32 months, supporting supply readiness as its NB1 trial advances.
No clinical results were presented; the update positions the program for pivotal-study scale manufacturing.
Management framed the outcome as improved flexibility for manufacturing, storage, distribution planning, inventory control, and lot sizing.
NB1 combines rhNELL-1 with demineralized bone matrix, targeting controlled bone regeneration in spine fusion procedures.
The multicenter randomized pilot study in Australia targets up to 30 patients with degenerative disc disease undergoing lumbar interbody fusion; enrollment is progressing.
BBLG•
